The article provides an overview of analyst ratings for C4 Therapeutics in the last 3 months. The average 12-month price target has decreased by 39.44% from the previous average, indicating a mixed outlook for the stock. This information is relevant and important for investors as it provides insight into the potential short-term price direction of the stock. The confidence in the analysis is high as it is based on the data provided in the article.